3/6/2025 12:51:53 PM Year of the NewCo? China’s emerging impact on global drug development By Sean Hess In 2024 biotech venture funding in Europe and the US saw a promising increase, reaching a total of $28.1 billion up from $21.2 billion...
2/5/2025 2:23:16 PM Technology Transfer block exemption review - what do tech and life sciences companies need to know? By Sophie Lawrance The Commission is taking its regular look at the competition rules and guidance applicable to technology licensing agreements, in advance...
1/29/2025 12:04:49 PM Doughnot forget about your franchisees! By Naina Patel The recent social media discussions around the well-known dessert company, Doughnut Time, are a reminder to franchise owners and...
1/24/2025 5:25:33 PM Termination Rights Gone Wrong: Lessons from the Zaha Hadid Case By Alan Sansom Wes Walker In late 2024, Mr. Justice Adam Johnson delivered his judgment in Zaha Hadid Ltd v Zaha Hadid Foundation [2024] EWHC 3325 (Ch), offering...
1/21/2025 2:05:31 PM In fashion: Biologically engineered luxury goods By Laura Harwood Camille Beckmann As with most industries, sustainability has become a key focus for the fashion and luxury goods industry. In recent years, this has led...
12/12/2024 11:50:02 AM SynbiTECH 2024: Engineering biology’s promise for the future By Ellen Lambrix In London last week, over 400 attendees and speakers gathered together for the fifth annual SynbiTECH conference in London. The event...
11/22/2024 3:51:47 PM Gene therapies and regulatory milestone triggers: Licensors and Licensees beware By Ellen Lambrix Luca Cericola As briefly mentioned in our article last week on Priority Review Vouchers, the financial terms of a biopharma patent licence agreement...
11/13/2024 1:07:00 PM Licensing content to train AI - essential points to consider By Emily Ryder The licensing of content for AI model training is on the rise. Amid reports that developers are facing a scarcity of content to train AI...
11/11/2024 10:31:26 AM Priority Review Vouchers: another high value sale generates a significant return for licensor By Ellen Lambrix Luca Cericola On 5 November 2024, Acadia Pharmaceuticals Inc. ("Acadia") announced that it sold its rare paediatric disease priority review voucher...
11/6/2024 12:34:01 PM Podcast: EU AI Act - impact on contracts and deals By Camille Beckmann Vik Khurana Anneke Pol In this episode, Camille Beckmann speaks to Anneke Pol and Vik Khurana (along with a special guest AI chatbot!) on how to structure...
10/30/2024 2:40:59 PM The first naked anti-TROP2 antibody progresses to a Phase 1/2a clinical trial By Matthew Warren Luca Cericola James Johnston On 24 October 2024, Cancer Research UK ("CRUK") and KisoJi Biotechnology Inc. ("KBI") announced that they have entered into an agreement...
10/8/2024 11:09:47 AM Licensing content to train AI – an emerging frontier? By Emily Ryder Reports abound in the media about AI companies entering into licensing deals with organisations including media organisations and other...